General MedicationsSUBCUTANEOUSStandard

YEZTUGO

LENACAPAVIR SODIUM

Standard Dose

EQ 463.5MG BASE/1.5ML (EQ 309MG BASE/ML)

Max Dose

Refer to approved labeling

Primary Use

Review priority: PRIORITY Marketing status: Prescription

Summary

Approval overview YEZTUGO is listed in Drugs@FDA under application 220018 (NDA).

Review priority: PRIORITY Marketing status: Prescription Active ingredient LENACAPAVIR SODIUM Form and strength SOLUTION;SUBCUTANEOUS - EQ 463.5MG BASE/1.5ML (EQ 309MG BASE/ML) Sponsor GILEAD SCIENCES INC Submission history Latest submission status date: 2025-06-18 00:00:00.

Structured Monograph

Clinical summary

Approval overview YEZTUGO is listed in Drugs@FDA under application 220018 (NDA). Review priority: PRIORITY Marketing status: Prescription Active ingredient LENACAPAVIR SODIUM Form and strength SOLUTION;SUBCUTANEOUS - EQ 463.5MG BASE/1.5ML (EQ 309MG BASE/ML) Sponsor GILEAD SCIENCES INC Submission history Latest submission status date: 2025-06-18 00:00:00. Submission type: ORIG.

Monitoring

• Marketing status: Prescription
• Review priority: PRIORITY

Interaction Notes

No interaction notes stored yet.